This report looks into 22 years (2000 – 2022) of FDA Drug GMP 483s.
The analyses reviewed in this report can be used to target internal remediation and inspection preparation efforts; due diligence inspections; to target supplier and Contract Manufacturing Organization (CMO) inspections; training purposes; and myriad other compliance improvement efforts.